Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Still a Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $27.45, but opened at $29.03. Chugai Pharmaceutical shares last traded at $27.7925, with a volume of 36,343 shares changing hands.

Analysts Set New Price Targets

Several research firms have recently commented on CHGCY. UBS Group upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

The stock has a market cap of $92.34 billion, a P/E ratio of 32.25 and a beta of 0.69. The firm’s 50 day moving average is $29.02 and its 200 day moving average is $27.00.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.25 EPS for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. The firm had revenue of $2.25 billion during the quarter.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.